Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2004
[Value of 18F-FDG PET in clinical staging of non-small-cell lung cancer].
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Su-Wen, Yu Jin-Ming, Xing Li-Gang
Аннотация
OBJECTIVE: To evaluate the feasibility of 18F-deoxyglucose positron emission tomography (18F-FDG PET) in the staging of non-small-cell lung cancer (NSCLC).
METHODS: 105 patients with NSCLC had been examined by 18F-FDG PET and staged by PET before radiotherapy. The results of 18F-FDG PET examination were compared with those of CT.
RESULTS: The staging was changed in 38 patients because of 18F-FDG PET findings with PET upstaged in 31 patients and downstaged in 7 patients. Because of distant metastasis detected by PET, 21 patients received palliative treatment. Six of the 7 downstaged patients underwent radical surgery, among which the PET findings were concordant with the operative findings in 5 patients. Distant metastasis detected by PET increased with elevation of pre-PET stage: at stage I 10.0% (2/20), stage II 14.3% (3/21) and stage III 25.0% (16/64), respectively.
CONCLUSION: 18F-FDG PET, by changing clinical staging in 36.2% (38/105) NSCLC patients has impact on treatment strategy in NSCLC patients.
METHODS: 105 patients with NSCLC had been examined by 18F-FDG PET and staged by PET before radiotherapy. The results of 18F-FDG PET examination were compared with those of CT.
RESULTS: The staging was changed in 38 patients because of 18F-FDG PET findings with PET upstaged in 31 patients and downstaged in 7 patients. Because of distant metastasis detected by PET, 21 patients received palliative treatment. Six of the 7 downstaged patients underwent radical surgery, among which the PET findings were concordant with the operative findings in 5 patients. Distant metastasis detected by PET increased with elevation of pre-PET stage: at stage I 10.0% (2/20), stage II 14.3% (3/21) and stage III 25.0% (16/64), respectively.
CONCLUSION: 18F-FDG PET, by changing clinical staging in 36.2% (38/105) NSCLC patients has impact on treatment strategy in NSCLC patients.